Benlysta, an experimental lupus drug from Human Genome Sciences, improved symptoms in 58% of patients who received a high dose, compared with 44% of those given placebo, according to a late-stage study involving 865 participants. The findings satisfy the guidelines for success set by HGS and the FDA.

Related Summaries